Amendment to Securities Purchase Agreement

On July 3, 2026, China SXT Pharmaceuticals Inc. entered into a securities purchase agreement with an institutional investor for the sale of Class A ordinary shares, with a principal amount of up to $31,500,000. Initially, a 1-for-80 share consolidation adjusted the floor price to $16.00 per share. However, on August 27, 2026, an amendment was made to reduce the floor price back to $0.20 per share. This amendment also involved filing an amendment to the company's registration statement on Form F-3. The agreement remains in full force and effect, governed by the laws of the State of New York.